非手术治疗雄激素性脱发的疗效:系统综述与网状Meta分析
该网状Meta分析纳入78项研究(其中22项可进行网状Meta分析),比较六种常见非手术治疗雄激素性脱发的疗效。相对效应显示低能量激光疗法(LLLT)为最优治疗,富血小板血浆(PRP)、非那雄胺1 mg(男性)、非那雄胺1 mg(女性)、米诺地尔5%、米诺地尔2%和度他雄胺(男性)在平均毛发计数变化上大致等效。米诺地尔5%和2%报告的药物相关不良事件最多(分别为n=45和n=23)。证据质量总体偏低,作者认为需要高质量随机对照试验和头对头试验来支持这些发现。
要点
- 低能量激光疗法(LLLT)在网状Meta分析中显示为最优治疗。
- PRP、非那雄胺1 mg、米诺地尔5%/2%和度他雄胺(男性)在毛发计数变化上大致等效。
- 米诺地尔5%和2%报告的药物相关不良事件分别为n=45和n=23。
核心结论
- 网状Meta分析结果表明,新型非激素疗法作为脱发有效治疗手段正在出现,但证据质量总体偏低。
- 需要高质量随机对照试验和头对头试验来支持这些发现,并帮助制定更标准化的方案,尤其是针对PRP。
- 该分析可能有助于医生临床决策,并突出患者可选择的多种非手术毛发修复方案。
研究设计与样本
- 研究类型为系统综述与网状Meta分析(NMA),检索现有文献。
- 纳入78项符合入选标准的研究,其中22项研究具备进行网状Meta分析所需数据。
- 比较六种最常见的非手术治疗方案:度他雄胺0.5 mg、非那雄胺1 mg、低能量激光疗法(LLLT)、米诺地尔2%、米诺地尔5%和富血小板血浆(PRP),对象为男性和女性雄激素性脱发患者。
主要发现
- 相对效应显示LLLT为最优治疗。
- 相对效应显示PRP、非那雄胺1 mg(男性)、非那雄胺1 mg(女性)、米诺地尔5%、米诺地尔2%和度他雄胺(男性)在治疗后平均毛发计数变化上大致等效。
- 米诺地尔5%和米诺地尔2%报告的药物相关不良事件最多,分别为n=45和n=23。
- 证据质量:米诺地尔2%对比米诺地尔5%为高;米诺地尔5%对比安慰剂为中;度他雄胺(男性)对比安慰剂、非那雄胺(女性)对比安慰剂、米诺地尔2%对比安慰剂、米诺地尔5%对比LLLT为低;非那雄胺(男性)对比安慰剂、LLLT对比假照射、PRP对比安慰剂、非那雄胺对比米诺地尔2%为极低。
临床怎么用
- 该分析可能有助于医生临床决策,并突出患者可选择的多种非手术毛发修复方案。
- 作者认为需要高质量随机对照试验和头对头试验来支持这些发现,并帮助制定更标准化的方案,尤其是针对PRP。
局限性
- 证据质量总体偏低。
- 作者指出需要高质量随机对照试验和头对头试验来支持这些发现,并帮助制定更标准化的方案,尤其是针对PRP。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Androgenetic alopecia, or male/female pattern baldness, is the most common type of progressive hair loss disorder. The aim of this study was to review recent advances in non-surgical treatments for androgenetic alopecia and identify the most effective treatments. A network meta-analysis (NMA) was conducted of the available literature of the six most common non-surgical treatment options for treating androgenetic alopecia in both men and women; dutasteride 0.5 mg, finasteride 1 mg, low-level laser therapy (LLLT), minoxidil 2%, minoxidil 5% and platelet-rich plasma (PRP). Seventy-eight studies met the inclusion criteria, and 22 studies had the data necessary for a network meta-analysis. Relative effects show LLLT as the superior treatment. Relative effects show PRP, finasteride 1 mg (male), finasteride 1 mg (female), minoxidil 5%, minoxidil 2% and dutasteride (male) are approximately equivalent in mean change hair count following treatment. Minoxidil 5% and minoxidil 2% reported the most drug-related adverse events (n = 45 and n = 23, respectively). The quality of evidence of minoxidil 2% vs. minoxidil 5% was high; minoxidil 5% vs. placebo was moderate; dutasteride (male) vs. placebo, finasteride (female) vs. placebo, minoxidil 2% vs. placebo and minoxidil 5% vs. LLLT was low; and finasteride (male) vs. placebo, LLLT vs. sham, PRP vs. placebo and finasteride vs. minoxidil 2% was very low. Results of this NMA indicate the emergence of novel, non-hormonal therapies as effective treatments for hair loss; however, the quality of evidence is generally low. High-quality randomized controlled trials and head-to-head trials are required to support these findings and aid in the development of more standardized protocols, particularly for PRP. Regardless, this analysis may aid physicians in clinical decision-making and highlight the variety of non-surgical hair restoration options for patients.
引用
- Gupta AK, Mays RR, Dotzert MS, et al. Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis. J Eur Acad Dermatol Venereol. 2018. PMID: 29797431. doi:10.1111/jdv.15081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。